SLXNW · Silexion Therapeutics Corp · Executive Compensation
$0.00
+0.00 (+0.00%)
At close · Nov 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, we had cash and cash equivalents of $4.8 million. Based on our current cash balance, as well as our history of operating losses and negative cash flows from operations, combined with our anticipated use of cash to, among other things, (i) fund the clinical development of SIL204, (ii) identify and develop new product candidates, and (iii) seek approval for SIL204 and any other product candidates we may develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and nine-month periods ended September 30, 2026 included in this quarterly report, but rather, for only several months from the filing date of this quarterly report, under our current business plan, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
Market Cap
$974,292
Shares
649,528
Volume · Nov 19
300
Avg daily vol (3M)
39.06K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ilan Hadar | Chief Executive Officer (formerly Managing Director of Silexion Israel) | $1,540,628 |
| Dr. Mitchell Shirvan | Chief Scientific and Development Officer | $1,301,490 |
| Mirit Horenshtein Hadar | Chief Financial Officer (formerly EVP Finance of Silexion Israel) | $770,090 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ilan Hadar | Chief Executive Officer (formerly Managing Director of Silexion Israel) | $253,614 |
| Dr. Mitchell Shirvan | Chief Scientific and Development Officer | $206,800 |
| Mirit Horenshtein Hadar | Chief Financial Officer (formerly EVP Finance of Silexion Israel) | $26,238 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
Amnon Peled
“Professor Peled’s resignation did not arise or result from any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.”
|
member of the Board | Resigned | 2026-07-31 |
| Ilan Levin | member of the Board | Terminated | 2026-03-25 |
| Amnon Peled | independent director | Appointed | 2024-12-10 |
|
Ilan Shiloah
“Mr. Shiloah’s decision to resign stemmed from competing demands on his time, and did not arise or result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
independent director serving on the board of directors | Resigned | 2024-09-19 |
| Shlomo Noy | Director | Appointed | 2024-08-21 |
| Ilan Shiloah | Director | Appointed | 2024-08-21 |
| Ilan Levin | Director | Appointed | 2024-08-21 |
| Avner Lushi | Director | Appointed | 2024-08-21 |
| Ruth Alon | Director | Appointed | 2024-08-21 |
| Dror Abramov | Director | Appointed | 2024-08-21 |
| Ilan Hadar | Chairman | Appointed | 2024-08-21 |
| Mitchell Shirvan | Chief Scientific and Development Officer | Appointed | 2024-08-21 |
| Mirit Horenshtein Hadar | Chief Financial Officer | Appointed | 2024-08-21 |
| Ilan Hadar | Chief Executive Officer | Appointed | 2024-08-21 |
Leadership
- Ilan Hadar CEO, Chairman
- Mirit Horenshtein Hadar CFO
- Amnon Peled Board Member
- Avner Lushi Board Member
- Dror Abramov Board Member
- Ilan Levin Board Member
- Ilan Shiloah Board Member
- Ruth Alon Board Member
- Shlomo Noy Board Member
Key facts
CIK
2022416
CUSIP
G1281K148
13F (30d)
27 filings
21 filers
Visit website
Investor relations